Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Diamanti

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Neurobiology of Disease|June 24, 2008
Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicityGiuseppe Pollio, Jeroen J M Hoozemans, Claus A Andersen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 19, 2016
Multimodal molecular imaging system for pathway-specific reporter gene expressionMarco Rossi, Luisa Massai, Daniela Diamanti, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Nature Chemical Biology|April 8, 2015
siRNA screen identifies QPCT as a druggable target for Huntington's diseaseMaria Jimenez-Sanchez, Wun Lam, Michael Hannus, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Neurobiology of Disease|June 24, 2008
Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicityGiuseppe Pollio, Jeroen J M Hoozemans, Claus A Andersen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 19, 2016
Multimodal molecular imaging system for pathway-specific reporter gene expressionMarco Rossi, Luisa Massai, Daniela Diamanti, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Nature Chemical Biology|April 8, 2015
siRNA screen identifies QPCT as a druggable target for Huntington's diseaseMaria Jimenez-Sanchez, Wun Lam, Michael Hannus, et al.
Pageof 3